Advances in personalized treatment of small cell lung cancer
10.3969/j.issn.1000-8179.2017.12.171
- VernacularTitle:小细胞肺癌个体化治疗进展
- Author:
Shuang ZHANG
;
Jingjing LIU
;
Ying CHENG
- Keywords:
small cell lung cancer;
first-line therapy;
second-line therapy;
molecular-target therapy;
immune checkpoint inhibitors
- From:
Chinese Journal of Clinical Oncology
2017;44(12):571-576
- CountryChina
- Language:Chinese
-
Abstract:
Small cell lung cancer (SCLC) is a lethal malignancy characterized by rapid growth, early metastatic spread, and unfavorable survival outcomes. Optimizing treatment for patients with SCLC has been the focus for investigators. The emergence of precision medi-cine and personalized treatment brought significant breakthroughs into SCLC treatment and changed the therapeutic model. The de-velopment of molecular bioinformatics increased our understanding of complex molecular mechanisms of SCLC, and novel targets for personalized treatment have been developed. Clinical trials testing these targets are ongoing, which show the potential of personal-ized treatment for SCLC.
